What are bispecific antibodies?

Tocilizumab's Role in Protecting Multiple Myeloma Patients on Bispecific Antibody TherapyПодробнее

Tocilizumab's Role in Protecting Multiple Myeloma Patients on Bispecific Antibody Therapy

CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite S...Подробнее

CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite S...

Rapid Generation of Bispecific Antibodies by Bio-Rad's SpyLock TechnologyПодробнее

Rapid Generation of Bispecific Antibodies by Bio-Rad's SpyLock Technology

The impact of prior bendamustine exposure on outcomes of bispecific antibodies in R/R FLПодробнее

The impact of prior bendamustine exposure on outcomes of bispecific antibodies in R/R FL

Rapid Generation of Bispecific Antibodies through Engineered Reversibly Inhibitable SpyCatcher.Подробнее

Rapid Generation of Bispecific Antibodies through Engineered Reversibly Inhibitable SpyCatcher.

Understanding Bispecific AntibodiesПодробнее

Understanding Bispecific Antibodies

Does the relative dose intensity of bispecific antibodies matter in patients with multiple myeloma?Подробнее

Does the relative dose intensity of bispecific antibodies matter in patients with multiple myeloma?

Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of LymphomaПодробнее

Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma

Dr Banerjee on Bispecific Antibody Treatment De-Escalation Strategies in Relapsed MyelomaПодробнее

Dr Banerjee on Bispecific Antibody Treatment De-Escalation Strategies in Relapsed Myeloma

Moving Bispecific Antibodies Upfront in Follicular LymphomaПодробнее

Moving Bispecific Antibodies Upfront in Follicular Lymphoma

Bispecific Antibody, AZD0486 Attacks a New Target in DLBCL | Sameh Gaballa, MD | #ASH24Подробнее

Bispecific Antibody, AZD0486 Attacks a New Target in DLBCL | Sameh Gaballa, MD | #ASH24

Predicting mortality using body composition in patients with myeloma receiving bispecific antibodiesПодробнее

Predicting mortality using body composition in patients with myeloma receiving bispecific antibodies

Bispecific Antibody Use After CAR-T Failure for B-Cell Lymphoma | Megan Melody, MD, MS | #ASH24Подробнее

Bispecific Antibody Use After CAR-T Failure for B-Cell Lymphoma | Megan Melody, MD, MS | #ASH24

The growing importance of bispecific antibodies in the treatment of multiple myelomaПодробнее

The growing importance of bispecific antibodies in the treatment of multiple myeloma

Bispecific Antibodies for Diffuse large B-cell lymphoma with Lorenzo Falchi, MDПодробнее

Bispecific Antibodies for Diffuse large B-cell lymphoma with Lorenzo Falchi, MD

CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24Подробнее

CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24

Bispecific Antibodies in LymphomaПодробнее

Bispecific Antibodies in Lymphoma

Myeloma: Real-World Use of Bispecific Antibodies in Community Oncology | Lisa Herms, PhD | #ASH24Подробнее

Myeloma: Real-World Use of Bispecific Antibodies in Community Oncology | Lisa Herms, PhD | #ASH24

Premium BsAb: Intact Mass-Driven Purification for High-Purity Bispecific AntibodiesПодробнее

Premium BsAb: Intact Mass-Driven Purification for High-Purity Bispecific Antibodies

Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024Подробнее

Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024